GH Research

GHRS

Market cap $978M

15.76 USD

-0.22

1.38%

At close Updated Mar 10, 4:00 PM EDT

Pre-market

After hours

15.80

+0.04

0.25%

1 day

-1.38%

5 days

2.34%

1 month

2.8%

3 months

10.91%

6 months

22.27%

Year to date

19.03%

1 year

40.71%

5 years

-18.13%

10 years

-18.13%

About: GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Employees: 50

Healthcare Biotechnology